what are the prospects of Biocon?

Ans: NO

Ans: good

Disclaimer: Investments in securities are subject to market RISKS. Read all the related documents carefully before investing. Please consult your appointed/paid financial adviser before taking any decision. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Ans: Serum Institute Life Sciences will now double its investment in Biocon Biologics from $150 million that was announced earlier in 2021 to $300 million. This is good news to hold the stock.

Ans: Biocon Q4FY23 revenue surges ~57% led by biosimilars
News
Revenue grew 56.7% YoY to Rs 3,773.9 crore; biosimilars grew 114% to Rs 2,102 crore and research services grew 31.2% to Rs 994.4 crore. EBITDA margin expanded 185 bps YoY to 26.4% and absolute EBITDA improved 68.5% to Rs 997.3 crore. Adjusted PAT stood at Rs 313.2 crore.
Views
The numbers were higher than estimates even after considering the full impact of Viatris acquisition. Biosimilars sales at Rs 2,100 crore exceeded management’s guidance of Rs 2,000 crore. GPM was in line and R&D was lower than expected. Overall, the progress on the biosimilars front, amid significant high leverage, will be key determinant for investors sentiments

Disclaimer: Investments in securities are subject to market RISKS. Read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.